The medical technology company Redsense Medical reports lower revenue and weaker earnings in the fourth quarter. Revenue fell 52.8 percent to SEK 6 million (12.7).Operating profit was SEK -2 million (5.5). Profit after tax was SEK -1.8 million (5.6). Earnings per share amounted to SEK -0.11 (0.34)."2025 marks the end of a year that focused on restructuring and operational adaptation. When I took over as CEO in October 2024, our priority was to build a more efficient and resilient organization. Over the past year, we have shifted the company's focus from short-term results to consistency and long-term execution — changes that are now visible in how the business is run. This has involved improved systems, clearer ownership, and better alignment between sales planning and production," says CEO Sebastien Bollue.He continues."Looking ahead to 2026, our priorities are clear. We will focus on disciplined growth by increasing usage among end customers in the USA, launching Redsense Clamp to the market anddeveloping selected new markets outside the USA, while we continue to place great emphasis on efficiency, cash flow, and internal resource utilization. The organization is now focusedon a smaller number of clear priorities."Getting the thumbs-up from the FDA for Clamp in the USA is one of the most important priorities for 2026, writes the Redsense Medical CEO. Redsense Medical, SEK millionQ4-2025Q4-2024ChangeNet sales612.7-52.8%Operating profit-25.5Operating margin43.3%Net income-1.85.6Earnings per share, SEK-0.110.34